Ikonisys

Ikonisys Equity

The The Equity of Ikonisys (ALIKO.PA) as of Oct 21, 2026 is 19.13 M EUR. In the previous year, The Equity was 14.25 M EUR — a change of 34.25% (higher).

Equity

19.13 MEUR

YoY

34.25%

Last updated:

In 2025, Ikonisys's equity was 19.13 M EUR, a 34.25% increase from the 14.25 M EUR equity in the previous year.

The Ikonisys Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
6.09 M EUR
Jan 1, 2020
5.70 M EUR
Jan 1, 2021
20.01 M EUR
Jan 1, 2022
17.67 M EUR
Jan 1, 2023
15.73 M EUR
Jan 1, 2024
14.25 M EUR
Jan 1, 2025
19.13 M EUR
The Ikonisys Equity history
YEAREquityYoY
19.13 MEUR+34.25%
14.25 MEUR-9.42%
15.73 MEUR-10.97%
17.67 MEUR-11.70%
20.01 MEUR+251.17%
5.70 MEUR-6.39%
6.09 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ikonisys Stock analysis

What does Ikonisys do? Ikonisys SA generates revenue through the sale of its cell diagnostic products, including oncoFISH bladder, oncoFISH her2, oncoFISH cervical, oncoFISH PTEN, oncoFISH ALK, and Explorer applications. These products are designed for cancer diagnosis, genetic disorder detection, and fertility testing, utilizing advanced molecular and immunological markers. The company's target customers are healthcare providers and clinical laboratories seeking accurate rare cell detection solutions. Ikonisys SA's offerings are tailored to specific medical applications such as bladder, breast, cervical, prostate, lung, and hematological cancer diagnostics, leveraging its proprietary Ikoniscope robotic components and digital microscope technology. The firm's product portfolio focuses on specialized diagnostic applications, with oncoFISH solutions targeting specific cancer types through molecular marker analysis. Explorer applications support hematological cancer diagnostics, while the underlying technology combines image acquisition, software engine, and digital microscopy for reliable cell detection. Ikonisys SA serves the healthcare sector by providing tools that enable precise diagnosis of genetic conditions and cancer types through its unique cellular analysis platform. Ikonisys SA's revenue streams are derived from the distribution of its diagnostic applications to clinical settings. The company's products are sold to healthcare institutions requiring advanced diagnostic capabilities for cancer, genetic disorders, and fertility issues. By offering targeted solutions like oncoFISH bladder for bladder cancer and oncoFISH her2 for breast cancer, Ikonisys SA addresses specific diagnostic needs within the medical field, utilizing its proprietary technology stack including Ikoniscope components and digital microscopy. Ikonisys is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Ikonisys's Equity

Ikonisys's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ikonisys's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ikonisys's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ikonisys's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ikonisys’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ikonisys stock

The Equity of Ikonisys is 19.13 M EUR in 2025.

The Equity of Ikonisys changed from 14.25 M EUR to 19.13 M EUR, representing a 34.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Ikonisys since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Ikonisys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Ikonisys

All Key Metrics — Ikonisys